<DOC>
	<DOCNO>NCT00160550</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability adjunctive treatment LEV ( 3,000 mg/day target dose 60 mg/kg/day child ) compare placebo reduce PGTC seizure subject ( 4 - 65 year ) suffer idiopathic generalize epilepsy uncontrolled despite treatment one two concomitant AEDs .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Levetiracetam Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subject confirm diagnosis consistent idiopathic generalize epilepsy experience primary generalize tonicclonic seizure ( IIE ) classifiable accord ILAE Classification Epileptic Seizures . Presence least 3 PGTC seizure 8week combined Baseline period . Absence brain lesion document CT scan MRI . An EEG perform within 1 year Visit 1 feature consistent PGTC seizure generalize idiopathic epilepsy . Male/female subject , &gt; =4 &lt; =65 year age Visit 1 . Subject stable dose one two AEDs baseline . Previous exposure levetiracetam . History partial seizure . History convulsive nonconvulsive status epilepticus take concomitant AEDs within three month prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Idiopathic Generalized Epilepsy , tonic-clonic seizure</keyword>
	<keyword>Levetiracetam , Keppra</keyword>
</DOC>